Skip to main content

Table 1 COVID-19 patient characteristics (n = 36)

From: Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses

Cohort characteristics no. %
Male 25 69
Age, years, median (range) 60.5 (25–77)
Symptom onset to sampling, days, median (range) 18 (9–53)
Days since diagnosis (positive SARS-CoV-2 PCR), median (range) 8 (1–44)
Comorbidities
 Diabetes mellitus type II 13 36
 Hypertension 11 31
 Lung disease 8 22
 Cardiovascular disease 7 19
 BMI > 25 6 17
 Malignancy 3 8
Treatment
 Supplemental oxygen 33 92
 Mechanical ventilation 9 25
 ICU addmissiona 14 39
 Immunomodulatory drugsb 14 39
 Antiviral treatment (remdesivir) 2 6
  1. aICU addmission before study sampling (n = 11), ICU treatment during study sampling (n = 2), ICU treatment after study sampling (n = 1)
  2. bTreatment before sampling corticosteroids (n = 13), tociluzimab (n = 2) or anakinra (n = 1). Two patients had prednisolone treatment before COVID-19 and had extra corticosteroids added as treatment